Aura Renewable Acquisiti... Share Discussion Threads

[clarky5150] 11/9/2007 10:38

like the look of this company and opened a small position last week. good upside potential here.

[february 30th] 10/8/2007 11:18

It's not surprising it doesn't catch investors' imagination - relatively large market capitalisation, large annual loss, tiny turnover. And the likelihood, in my opinion, of further placings before it becomes profitable. OK, if it was an oil exploration company it might get away with those fundamentals, but right now Ardana isn't in a red hot sector. Of course these things can change very quickly!

[knackers] 10/8/2007 11:03

For how much longer? Reckon we're going to see the PR handle being seriously cranked in the next 4-6 months. Newsflow will warrant it.

[vow] 10/8/2007 07:43

The most over looked Biotech on the market!

[knackers] 01/8/2007 16:04

Was able to buy off the bid today.

[gnomet2] 18/7/2007 22:16

Another mention in the IC



Even if we have to wait a bit longer for a deal - which could rocket the share price - I think phase II results for tev should be due very soon, and that could give the price a nice lift.

[n_w_b] 07/7/2007 08:00

Buy tip from yesterdays Investors Chronicle:

"Our pipeline is maturing very nicely" boasts chief exec Maureen Lindsay. Certainly, the Scottish biotech now has three products on the market following the deal last year with Novartis to promote overactive blabber treatment Emselex in the UK, and a burgeoning pipeline of late-stage drugs.

The company's Testosterone cream recently entered Phase III testing, and a study of Ardana's growth-hormone deficiency diagnostic, GHS, is also underway. Both products are expected to launch in 2008, while erectile dysfunction product Invicorp is due to launch in the UK and Germany.

The long-awaitied deal for Teverelix, the company's treatment for prostate cancer, benign hyperplasia(BHP) and emndometriosis, has not yet materialised, but Ms Lindsay says it remains Ardana's "Top priority" and discussions are in the late stages. The BHP market alone is worth almost $5bn(£2.5m) in annual sales.

So, overall, product sales were down on last year, but finance director Graham Lee blames this on lumpy revenues from third party distributors in Europe. House broker Piper Jaffray is updating forecasts, but notes that the full-year loss was lower than its forecast.

[joan of arc] 29/6/2007 08:08

Good grief - well spotted.

[goodgrief] 29/6/2007 06:41

A couple of articles in today's papers

[gnomet2] 15/6/2007 20:55

Did they make any interesting comments? We were told that there would be results from the phase 2 trials in prostate and benign whotnot by end of H1, and ideally the big deal to fund the phase 3 s. Let's hope Piper J's judgement and fair price target for this share is realistic

[anusol] 15/6/2007 12:14

not much chat on here - usually seen as a good thing?
I read the IC buy tip today and quite interested in ARA, and seem to have a good line of products coming to the market over next 5 yrs. Expected it blue today. Just wondering when the right time to buy in is?

[fickena] 05/4/2007 13:28

Welcome aboard Doc,

I used to have a tactic of covering many biotechs with the hope that one would come good and make me the returns. Although I was lucky with a couple, like AZM and OXB, I also have numerous failures.

I am now sticking to ARA, PTI, VER and will buy AZM again if it falls or breaks the 120p barrier.

In regards to ARA hopefully this has been a double bottom and we can look forward from here. Volumes have picked up, but are no where near where they need to be.

Hopefully as the word spreads.

[dr biotech] 05/4/2007 13:16

I picked up a few of these earlier this week - I'm trying to think about shorter term holdings rather than the "hold & regret" tactic I've used in the past. I think going for companies with later stage products seems to be more reqarding than the higher risk ones that are too distant from becoming profitable (of course there are the exceptions such as SPA whose price I still can't quite believe but of course I never held them). Hopefully 108 was the bottom, it seemed to bounce twice from there.

[n_w_b] 03/4/2007 14:47

They're exibiting this week in Birmingham:

[fickena] 03/4/2007 14:28

ticking up nicely again.

[knackers] 02/4/2007 19:29

Share overhang cleared(?). The manifestation of that of course will be in the SP's performance over the coming weeks. Time we cleared north of this tiresome trading range m'thinks.

[tobie_1] 02/4/2007 16:35

A lot of trades today. Any thoughts?

[flagon] 27/3/2007 08:50

I too have recently bought in here. Also holding both ASM & OXB. When one of these biotech's or any other get taken out or sign a licensing deal investor attention will focus on this sector IMHO. Good place to be at the moment.


Good luck,


Flagon

[mercury123] 27/3/2007 08:21

Well having read my way through the thread on this one I've decided to buy in at 1.085. It's another one like AZM which I also follow. Waiting for that elusive licensing deal but no bad news so far on the development of its' key drug and everything to play for........

[alanrex] 18/3/2007 19:37

what did it say?

[n_w_b] 16/3/2007 07:34

Mentioned yesterday in shares Mag. "Making Money from biotechnology and pharmaceuticals:"